The IC Evaluation and Diagnosis Algorithm—developed by Janssen Pharmaceuticals, Inc., and reviewed by a panel of Janssen Pharmaceuticals, Inc. consultants—offers clear step-by-step guidance to assess a patient's condition during an initial consultation.
IC Evaluation and Diagnosis Algorithm
Download PDF 
Download the free Adobe® Reader® plug-in.
The IC Treatment Algorithm—developed by Janssen Pharmaceuticals, Inc., and reviewed by a panel of Janssen Pharmaceuticals, Inc. consultants—offers step-by-step guidance to develop a multimodal treatment plan for patients suffering from IC.
IC Treatment Algorithm
Download PDF
Download the free Adobe® Reader® plug-in.
Important Safety Information
- Contraindications: ELMIRON® is contraindicated in patients with known hypersensitivity to the drug, structurally related compounds, or excipients
- Anticoagulant Activity: ELMIRON® is a weak anticoagulant (blood thinner) which may increase bleeding. Patients undergoing invasive surgery or having signs/symptoms of underlying coagulopathy or other increased risk of bleeding (due to anticoagulant therapy or high doses of anti-inflammatory drugs) should be evaluated for the risk of hemorrhage
- Alopecia: In clinical trials of ELMIRON®, alopecia began within the first 4 weeks of treatment. Ninety-seven percent (97%) of the cases of alopecia reported were alopecia areata, limited to a single area on the scalp
- Use in Pregnancy: ELMIRON® is a Pregnancy Category B drug
- Most Common Adverse Reactions (frequency 1% to 4%): Alopecia (4%), diarrhea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%), dizziness (1%)